Prevention and treatment of congestive heart failure in diabetic patients;Prevención y tratamiento de la insuficiencia cardíaca en los pacientes diabéticos

Revista Espanola de Cardiologia

Volumn 55, Issue 10, 2002, Pages 1083-1087

  Anguita Sánchez, Manuel ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Cardiomyopathy; Diabetes; Heart failure

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IRBESARTAN; LISINOPRIL; LOSARTAN; METOPROLOL; VALSARTAN;

ARTICLE; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFECT; HUMAN; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; RISK FACTOR;

EID: 0036811927     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-8932(02)76759-6     Document Type: Article

References (27)

1. American Diabetes Association, the National Heart, Lung and Blood Institute; the Juvenile Diabetes Foundation International; the National Institute of Diabetes and Digestive and Kidney Disease, and the American Heart Association. Diabetes mellitus: a major risk factor for cardiovascular Disease. Circulation 1999; 100:1132-3.
2. Mak KH, Topol EJ. Emerging concepts in the management of acute myocardial infarction in patients with diabetes mellitus. J Am Coll Cardiol 2000;35:563-8.
3. Capes SE, Hunt D, Malmberg K. Stress hyperglycemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systemic overview. Lancet 2000;355:773-8.
4. Francis GS. Diabetic cardiomyopathy: fact or fiction? Heart 2001;85:247-8.
5. Van Hoeven KH, Factor SM. Diabetic heart disease: the clinical and pathological spectrum-part I. Clin Cardiol 1989;12:600-4.
6. Van Hoeven KH, Factor SM. Diabetic heart disease: the clinical and pathological spectrum-part II. Clin Cardiol 1989;12:667-71.
7. Fein FS, Sonnenblick EH. Diabetic cardiomyopathy. Prog Cardiovasc Dis 1985;27:255-70.
8. Fein FS, Sonnenblick EH. Diabetic cardiomyopathy. Cardiovasc Drugs Ther 1994;8:65-73.
9. Galderisi M, Anderson KM, Wilson PWF. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol 1991;68:85-9.
10. Rutler S, Dlugash J, Yuceoglu YZ. New type of cardiomyopathy associated with diabetic glomerular sclerosis. Am J Cardiol 1972;30:595-602.
11. García MJ, McNamara PM, Kannel WB. Morbidity and mortality in diabetics in the Framingham population: sixteen-year follow up study. Diabetes 1974;23:105-11.
12. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham Study. Am J Cardiol 1974;34:29-34.
13. Zuanetti G, Latini R, Maggioni AP, Santoro L, Franzosi MG, and the GISSI-2 Investigators. Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI 2 study. J Am Coll Cardiol 1993;22:1788-94.
14. Devereux RB, Roman MJ, Paranicas M. Impact of diabetes on cardiac structure and function. The strong heart study. Circulation 2000;101:2271-6.
15. Flatter MD, Kober L, Pfeffer MA. Meta-analysis of individual patient data from trials of long-term ACE-inhibitor treatment after acute myocardial infarction. Circulation 1997;96(Suppl 8): 1706.
16. Bristow MR, Gilbert EM, Abraham WT, for the MOCHA Investigators. Effect of carvedilol on left ventricular function and mortality in diabetic versus non-diabetic patients with ischemic or non-ischemic dilated cardiomyopathy. Eur Heart J 1996; 17(Suppl):78.
17. Ryden L, Armstrong P, Cleland JGF, for the ATLAS Investigators. High dose ACE-inhibitor strategy is more effective than low-dose in diabetic patients with congestive heart failure. J Am Coll Cardiol 1999;33(Suppl A): 188.
18. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: the MERIT-HF Study. Lancet 1999;353:2001-7.
19. Melchior T, Kober L, Madsen CR. Accelerating impact of diabetes mellitus on mortality in the years following an acute myocardial infarction. Eur Heart J 1999;20:973-8.
20. Senni M, Tribouilloy CM, Rodeheffer RL, Jacobsen SJ, Evans JM, Bailey KR, et al. Congestive heart failure in the Community. A study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998;98:2282-9.
21. Shindler DM, Kostis JF, Yusuf S, for the SOLVD Investigators. Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction trials and registry. Am J Cardiol 1996;77:1017-20.
22. Tan LG, Chang DS, Lukman LF. Irbesartan decreases atrial natriuretic peptide levels and improves ejection fraction in diabetic patients with congestive heart failure. Cardiovasc Drugs Ther 1999;13:13.
23. Pitt B, Segal R, Martinez FA, for the ELITE 1 Investigators. Randomized trial of losartan versus captopril in patients over 65 with heart failure. Lancet 1997;349:747-52.
24. The HOPE Investigators. Effects of an angiotensin converting enzime inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
25. HOPE Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.
26. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al, for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
27. Mann JFE, Gerstein HC, Poque J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134:629-36.